Gilead ( GILD) estimates, price target were increased at Oppenheimer. Estimates were raised through 2014. Company can gain market share in Genotype 1 HCV, Oppenheimer said. Outperform rating and new $63 price target. Goldman Sachs ( GS) numbers raised at UBS. Earnings estimates were raised given better revenue outlook and buybacks, said UBS. Price target goes to $165. Johnson & Johnson ( JNJ) numbers were boosted at Jefferies. Shares are now seen reaching $95. Estimates also upped, given better pharmaceuticals growth, Jefferies said. Hold rating. Starbucks ( SBUX) price target was raised at Oppenheimer. Shares are now seen reaching $75. Company can continue to deliver strong sales and expand margins, Oppenheimer said. Outperform rating. Charles Schwab ( SCHW) numbers were raised at UBS. Earnings estimates were raised given NIM upside, said UBS. Price target goes to $21. >To submit a news tip, email: email@example.com. Follow TheStreet on Twitter and become a fan on Facebook.